Pioglitazone, PPAR? agonist, attenuates experimental autoimmune neuritis

Inflammation

Volumn 35, Issue 4, 2012, Pages 1338-1347

  Ramkalawan, Hhoonisha ^a   Wang, Yu Zhong ^a   Hurbungs, Ameet ^b   Yang, Yan Fang ^a   Tian, Fa Fa ^a   Zhou, Wen Bin ^a   Li, Jing ^a   Yang, Huan ^a   Xiao, Bo ^a   Zhang, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Anti inflammatory; Experimental autoimmune neuritis; NF B; Pioglitazone; PPAR?

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE NEURITIS; FEEDING; MALE; NEURITIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; DRUG POTENTIATION; LEWIS RAT; METABOLISM; RANDOMIZATION;

RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; NF-KAPPA B; PPAR GAMMA; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866642996     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9447-4     Document Type: Article

References (43)

1. Islam, Z., B.C. Jacobs,A. van Belkum, Q.D.Mohammad, M.B. Islam, P. Herbrink, S. Diorditsa, S.P. Luby, K.A. Talukder, and H.P. Endtz. 2010. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 74: 581-587.
2. Nelson, L., R. Gormley, M.S. Riddle, D.R. Tribble, and C.K. Porter. 2009. The epidemiology of Guillain-Barre syndrome in U. S. military personnel: A case-control study. BMC Research Notes 2: 171.
3. Hughes, R.A., A.V. Swan, and P.A. van Doorn. 2010. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database of Systematic Reviews: CD002063.
4. van Doorn, P.A., K. Kuitwaard, C. Walgaard, R. van Koningsveld, L. Ruts, and B.C. Jacobs. 2010. IVIG treatment and prognosis in Guillain-Barre syndrome. Journal of Clinical Immunology 30 (Suppl 1): S74-S78.
5. Alshekhlee, A., Z. Hussain, B. Sultan, and B. Katirji. 2008. Guillain-Barre syndrome: Incidence and mortality rates in US hospitals. Neurology 70: 1608-1613.
6. Xia, R.H., N. Yosef, and E.E. Ubogu. 2010. Clinical, electrophysiological and pathologic correlations in a severe murine experimental autoimmune neuritis model of Guillain-Barre syndrome. Journal of Neuroimmunology 219: 54-63.
7. Willson, T.M., P.J. Brown, D.D. Sternbach, and B.R. Henke. 2000. The PPARs: From orphan receptors to drug discovery. Journal of Medicinal Chemistry 43: 527-550.
8. Lefterova, M.I., D.J. Steger, D. Zhuo, M. Qatanani, S.E. Mullican, G. Tuteja, E. Manduchi, G.R. Grant, and M.A. Lazar. 2010. Cellspecific determinants of peroxisome proliferator-Activated receptor gamma function in adipocytes and macrophages. Molecular and Cellular Biology 30: 2078-2089.
9. Rogue, A., C. Spire, M. Brun, N. Claude, and A. Guillouzo. 2010. Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Research 2010: 325183.
10. Scotti, E., and P. Tontonoz. 2010. Peroxisome proliferator-Activated receptor gamma dances with different partners in macrophage and adipocytes. Molecular and Cellular Biology 30: 2076-2077.
11. Nissen, S.E., and K. Wolski. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine 356: 2457-2471.
12. Singh, S., Y.K. Loke, and C.D. Furberg. 2007. Long-Term risk of cardiovascular events with rosiglitazone: A meta-Analysis. Journal of the American Medical Association 298: 1189-1195.
13. Berger, J., P. Bailey, C. Biswas, C.A. Cullinan, T.W. Doebber, N.S. Hayes, R. Saperstein, R.G. Smith, and M.D. Leibowitz. 1996. Thiazolidinediones produce a conformational change in peroxisomal proliferator-Activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137: 4189-4195.
14. Lehmann, J.M., L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T. M. Willson, and S.A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-Activated receptor gamma (PPAR gamma). Journal of Biological Chemistry 270: 12953-12956.
15. Willson, T.M., J.E. Cobb, D.J. Cowan, R.W. Wiethe, I.D. Correa, S.R. Prakash, K.D. Beck, L.B. Moore, S.A. Kliewer, and J.M. Lehmann. 1996. The structure-Activity relationship between peroxisome proliferator-Activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. Journal of Medicinal Chemistry 39: 665-668.
16. Drew, P.D., J. Xu, and M.K. Racke. 2008. PPAR-gamma: Therapeutic potential for multiple sclerosis. PPAR Research 2008: 627463.
17. Hontecillas, R.,W.T. Horne, M. Climent, A.J. Guri, C. Evans, Y. Zhang, B.W. Sobral, and J. Bassaganya-Riera. 2011. Immunoregulatory mechanisms of macrophage PPAR-gamma in mice with experimental inflammatory bowel disease. Mucosal Immunology 4: 304-313.
18. Szanto, A., and L. Nagy. 2008. The many faces of PPARgamma: Anti-inflammatory by any means? Immunobiology 213: 789-803.
19. Klotz, L., M. Schmidt, T. Giese, M. Sastre, P. Knolle, T. Klockgether, and M.T. Heneka. 2005. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-Activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. Journal of Immunology 175: 4948-4955.
20. Hasegawa, H., H. Takano, Y. Zou, Y. Qin, K. Hizukuri, K. Odaka, T. Toyozaki, and I. Komuro. 2005. Pioglitazone, a peroxisome proliferator-Activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. Journal of Molecular and Cellular Cardiology 38: 257-265.
21. Dubuquoy, L., C. Rousseaux, X. Thuru, L. Peyrin-Biroulet, O. Romano, P. Chavatte, M. Chamaillard, and P. Desreumaux. 2006. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55: 1341-1349.
22. Rousseaux, C., B. Lefebvre, L. Dubuquoy, P. Lefebvre, O. Romano, J. Auwerx,D.Metzger,W.Wahli, B.Desvergne,G.C.Naccari, P. Chavatte, A. Farce, P. Bulois, A. Cortot, J.F. Colombel, and P. Desreumaux. 2005. Intestinal antiinflammatory effect of 5-Aminosalicylic acid is dependent on peroxisome proliferator-Activated receptor-gamma. The Journal of Experimental Medicine 201: 1205-1215.
23. Giaginis, C., A. Giagini, and S. Theocharis. 2009. Peroxisome proliferator-Activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. Pharmacological Research 60: 160-169.
24. Fogo, A.B. 2011. PPARgamma and chronic kidney disease. Pediatric Nephrology 26: 347-351.
25. Stienekemeier, M., T. Herrmann, N. Kruse, A. Weishaupt, F.X. Weilbach, G. Giegerich, A. Theofilopoulos, S. Jung, and R. Gold. 1999. Heterogeneity of T-cell receptor usage in experimental autoimmune neuritis in the Lewis rat. Brain 122(Pt 3): 523-535.
26. Chinetti, G., S. Griglio, M. Antonucci, I.P. Torra, P. Delerive, Z. Majd, J.C. Fruchart, J. Chapman, J. Najib, and B. Staels. 1998. Activation of proliferator-Activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. Journal of Biological Chemistry 273: 25573-25580.
27. Weishaupt, A., W. Bruck, T. Hartung, K.V. Toyka, and R. Gold. 2001. Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factoralpha. Neuroscience Letters 306: 77-80.
28. Lee, S.B., and J.S. Schorey. 2005. Activation and mitogen-Activated protein kinase regulation of transcription factors Ets and NF-kappaB in Mycobacterium-infected macrophages and role of these factors in tumor necrosis factor alpha and nitric oxide synthase 2 promoter function. Infection and Immunity 73: 6499-6507.
29. Taylor, B.S., M.E. de Vera, R.W. Ganster, Q. Wang, R.A. Shapiro, S.M. Morris Jr., T.R. Billiar, and D.A. Geller. 1998. Multiple NFkappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. Journal of Biological Chemistry 273: 15148-15156.
30. Xie, Q.W., H. Cho, Y. Kashiwabara, M. Baum, J.R. Weidner, K. Elliston, R. Mumford, and C. Nathan. 1994. Carboxyl terminus of inducible nitric oxide synthase. Contribution to NADPH binding and enzymatic activity. Journal of Biological Chemistry 269: 28500-28505.
31. Arnett, H.A., R.P. Hellendall, G.K. Matsushima, K. Suzuki, V.E. Laubach, P. Sherman, and J.P. Ting. 2002. The protective role of nitric oxide in a neurotoxicant-induced demyelinating model. Journal of Immunology 168: 427-433.
32. Zhu, J., E. Mix, and H. Link. 1998. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barre syndrome. Journal of Neuroimmunology 84: 40-52.
33. Zhu, J., E. Mix, T. Olsson, and H. Link. 1994. Cellular mRNA expression of interferon-gamma, IL-4 and transforming growth factor-beta (TGF-beta) by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clinical and Experimental Immunology 98: 306-312.
34. Villanueva, C.J., and P. Tontonoz. 2010. Licensing PPARgamma to work in macrophages. Immunity 33: 647-649.
35. Antonelli, A., S.M. Ferrari, P. Fallahi, S. Piaggi, A. Paolicchi, S.S. Franceschini, M. Salvi, and E. Ferrannini. 2011. Cytokines (interferon-gamma and tumor necrosis factor-Alpha)-induced nuclear factor-kappaB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 60: 277-283.
36. Bassaganya-Riera, J., R. Song, P.C. Roberts, and R. Hontecillas. 2010. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunology 23: 343-352.
37. Pascual, G., A.L. Fong, S. Ogawa, A. Gamliel, A.C. Li, V. Perissi, D.W. Rose, T.M. Willson, M.G. Rosenfeld, and C.K. Glass. 2005. A SUMOylation- dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437: 759-763.
38. Lu, M.O., and J. Zhu. 2011. The role of cytokines in Guillain-Barre syndrome. Journal of Neurology 258: 533-548.
39. Zhang, Z., Z.Y. Zhang, and H.J. Schluesener. 2009. Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. Journal of Immunology 183: 3081-3091.
40. Yuan, Z., Y. Liu, J. Zhang, C. Kishimoto, A. Ma, and Z. Liu. 2004. Peroxisome proliferator-Activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis associated with inhibition of self-sensitive T cells. Journal of Cardiovascular Pharmacology 43: 868-875.
41. Chung, S.W., B.Y. Kang, and T.S. Kim. 2003. Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferatoractivated receptor-gamma (PPAR-gamma) ligands: Involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. Molecular Pharmacology 64: 1169-1179.
42. Ruhl, R., A. Dahten, F.J. Schweigert, U. Herz, and M. Worm. 2003. Inhibition of IgE-production by peroxisome proliferatoractivated receptor ligands. The Journal of Investigative Dermatology 121: 757-764.
43. Saubermann, L.J., A. Nakajima, K. Wada, S. Zhao, Y. Terauchi, T. Kadowaki, H. Aburatani, N. Matsuhashi, R. Nagai, and R.S. Blumberg. 2002. Peroxisome proliferator-Activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflammatory Bowel Diseases 8: 330-339.